VIKING GLOBAL INVESTORS LP's Net Worth

$1.93 Billion

Estimate Recalculated Feb 22, 2024 09:07PM EST

Who is VIKING GLOBAL INVESTORS LP?

VIKING GLOBAL INVESTORS LP has an estimated net worth of $1.93 Billion. This is based on reported shares across multiple companies, which include FIRST DATA CORP, Wayfair Inc., Amylyx Pharmaceuticals, Inc., Adaptive Biotechnologies Corp, Zentalis Pharmaceuticals, Inc., RayzeBio, Inc., Editas Medicine, Inc., Inhibrx, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., PROCEPT BioRobotics Corp, BridgeBio Pharma, Inc., 4D Molecular Therapeutics, Inc., Rallybio Corp, Ginkgo Bioworks Holdings, Inc., APi Group Corp, FIGS, Inc., Urovant Sciences Ltd., Axovant Gene Therapies Ltd., and Frazier Lifesciences Acquisition Corp.

SEC CIK

VIKING GLOBAL INVESTORS LP's CIK is 0001103804

Past Insider Trading and Trends

2019 was VIKING GLOBAL INVESTORS LP's most active year for acquiring shares with 36 total transactions. VIKING GLOBAL INVESTORS LP's most active month to acquire stocks was the month of January. 2022 was VIKING GLOBAL INVESTORS LP's most active year for disposing of shares, totalling 22 transactions. VIKING GLOBAL INVESTORS LP's most active month to dispose stocks was the month of August. 2022 saw VIKING GLOBAL INVESTORS LP paying a total of $312,238,236.29 for 300,884,319 shares, this is the most they've acquired in one year. In 2020 VIKING GLOBAL INVESTORS LP cashed out on 11,750,813 shares for a total of $327,393,539.29, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Amylyx Pharmaceuticals, Inc. (AMLX) Snapshot price: $15.2775

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-10.26%
-1.40M
$29.80
-$41,719,639.31
12.24M
Sep 8 - Sep 9
Form 4
7.17M
$19.00
$43,700,000.00
7.17M
Jan 11 - Nov 11
Form 3
0
0
No matching records found

Adaptive Biotechnologies Corp (ADPT) Snapshot price: $3.58

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-3.23%
-1.00M
$55.65
-$55,650,000.00
29.99M
Dec 14
Form 4
-7.46%
-2.50M
$49.52
-$123,787,500.00
30.99M
Nov 11
Form 4
-12.79%
-4.91M
$24.98
-$122,706,039.29
33.49M
Jan 28
Form 4
+2,595.20%
36.98M
$20.00
38.41M
Jul 1
Form 3
0
0
No matching records found

Zentalis Pharmaceuticals, Inc. (ZNTL) Snapshot price: $11.57

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-11.25%
-500.00K
$50.50
-$25,250,000.00
3.94M
Dec 1
Form 4
+19.50%
725K
$18.00
$13,050,000.00
4.44M
Apr 7
Form 3
0
0
No matching records found

RayzeBio, Inc. (RYZB) Snapshot price: $62.13

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
6.64M
$18.00
6.64M
Sep 19
Form 4
6.64M
$18.00
6.64M
Sep 19
Form 3
0
0
Form 3
0
0
No matching records found

Editas Medicine, Inc. (EDIT) Snapshot price: $7.139

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4/A
5.46M
5.46M
Feb 8 - Feb 8
Form 4
5.46M
5.46M
Feb 8 - Feb 8
Form 3
0
0
No matching records found